Recordati SpA (CHIX:RECM) Loans Receivable: €0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:RECM Recordati SpA CHIX:RECM
93 GF Score
Price €51.38
GF Value €61.06
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Recordati SpA Loans Receivable?

Recordati SpA CHIX:RECM 93 Loans Receivable is €0 Mil as of Mar. 2026. GuruFocus rates CHIX:RECM with a GF Score™ of 93/100 and a GF Value™ of €61.06 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Recordati SpA's Loans Receivable for the quarter that ended in Mar. 2026 was €0 Mil.

Recordati SpA Loans Receivable Historical Data

* Premium members only.

The historical data trend for Recordati SpA's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recordati SpA Loans Receivable Chart

Recordati SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Recordati SpA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:RECM
93GF Score
Recordati SpA CHIX:RECM
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recordati SpA Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of €0 Mil mean?
Recordati SpA (CHIX:RECM) has a Loans Receivable of €0 Mil as of Mar. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Recordati SpA and its competitors.
Is Recordati SpA's Loans Receivable too high?
Recordati SpA's current Loans Receivable is €0 Mil. Overall, Recordati SpA has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's Loans Receivable compare to LLY and JNJ?
Recordati SpA's Loans Receivable of €0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Drug Manufacturers company?
A good Loans Receivable depends on the Drug Manufacturers industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Recordati SpA and its competitors. Recordati SpA's current Loans Receivable is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (CHIX:RECM) is currently considered Modestly Undervalued. The stock's GF Value™ is €61.06, compared to a current price of €51.38 — trading 15.9% below its estimated fair value. The current Loans Receivable is €0 Mil. Recordati SpA's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Recordati SpA (CHIX:RECM), the current Loans Receivable is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Recordati SpA (CHIX:RECM) Overvalued in 2026?

Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued. The current stock price of €51.38 is trading 15.9% below its estimated GF Value™ of €61.06. GuruFocus considers Recordati SpA to be Modestly Undervalued.

Key valuation signals for CHIX:RECM:

  • Loans Receivable: €0 Mil
  • GF Value™: €61.06 vs. price of €51.38 (15.9% below fair value)
  • GF Score™: 93/100 with 3 warning signs

No single metric tells the full story. See the CHIX:RECM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Recordati SpA Business Description

Address Via Matteo Civitali 1, MIlan, ITA, 20148
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
93GF Score

Get the complete analysis for CHIX:RECM

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€51.38
Price
€61.06
GF Value